Frontiers in Medicine · Nov 13, 2026
Pei Tu Sheng Ji electroacupuncture for sarcopenia and changes in serum C-terminal agrin fragment levels: protocol for a randomized, participant-blinded, sham-controlled trial
By Qingsong Liu, Zongrong Ng, Jie Wu et al.
Introduction: Sarcopenia is a progressive skeletal muscle disorder characterized by reduced muscle mass, decreased muscle strength, and impaired physical performance, which may increase the risk of falls, disability, reduced quality of life, and mortality. Although exercise training and nutritional support are foundational strategies, their implementation may be constrained by comorbidities, pain, restricted mobility, and adherence challenges. Pei Tu Sheng Ji electroacupuncture, grounded in the Traditional Chinese Medicine principle of "treating flaccidity disorder by selecting the Yangming meridian alone," may provide a feasible complementary approach. However, rigorous sham-controlled clinical evidence and biomarker-based evaluations remain limited. Methods and analysis: This single-center, randomized, participant-blinded, sham-controlled clinical trial will recruit 60 participants diagnosed with sarcopenia according to the age-stratified Asian Working Group for Sarcopenia (AWGS) 2025 criteria. Eligible participants will be randomly assigned in a 1:1 ratio to receive either Pei Tu Sheng Ji electroacupuncture plus standardized basic treatment or procedure-matched non-meridian, non-acupoint sham electroacupuncture plus the same standardized basic treatment. Basic treatment will be implemented in accordance with the AWGS 2025 consensus and will include exercise training, nutritional support, vitamin D correction when needed, and health education. The electroacupuncture or sham intervention will be administered three times weekly for 20 min per session over 28 days, totaling 12 sessions. The primary outcome will be the change in 6-meter gait speed from baseline to day 28. Secondary outcomes will include dual-energy X-ray absorptiometry-derived muscle mass, calf circumference, handgrip strength, the Short Physical Performance Battery, the 5-times sit-to-stand test, and serum biomarkers including the creatinine-to-cystatin C ratio, irisin, and C-terminal agrin fragment (CAF). The trial has been registered in the Chinese Clinical Trial Registry (ChiCTR2600122080). Discussion: This trial will evaluate whether Pei Tu Sheng Ji electroacupuncture provides additional benefits for walking ability, muscle function, and multidimensional sarcopenia-related outcomes relative to procedure-matched sham electroacupuncture, with both groups receiving the same AWGS-informed basic treatment. The exploratory assessment of CAF and other serum biomarkers may provide preliminary insight into neuromuscular junction-related responses to electroacupuncture.